Evidence map›Paper›PMID 41730958›Full record

ArticleScientific reports2026

Hydrogen sulfide rescues IFNγ/TNFα-induced intestinal epithelial barrier dysfunction by enhancing oxidative phosphorylation.

Janaíne Prata de Oliveira, Matthias van Sligtenhorst, Cansu Akkaya, Astrid Verbiest, Victoria Francelino Alves, Marie Wallays, Schalk van der Merwe, Marc Ferrante, Tim Vanuytsel, John L Wallace and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Janaíne Prata de Oliveira *Laboratory of Mucosal Biology, Hepatology Research Unit, Department of Chronic Diseases and Metabolism, KU Leuven, Herestraat 49, O&N1, Box 703, 3000, Leuven, Belgium.
Matthias van Sligtenhorst *Laboratory of Mucosal Biology, Hepatology Research Unit, Department of Chronic Diseases and Metabolism, KU Leuven, Herestraat 49, O&N1, Box 703, 3000, Leuven, Belgium.
Cansu AkkayaLaboratory of Mucosal Biology, Hepatology Research Unit, Department of Chronic Diseases and Metabolism, KU Leuven, Herestraat 49, O&N1, Box 703, 3000, Leuven, Belgium.
Astrid VerbiestTranslational Research Center for Gastrointestinal Disorders (TARGID), Leuven Intestinal Failure and Transplantation Center (LIFT), University of Leuven, Leuven, Belgium, University Hospitals Leuven, Leuven, Belgium.
Victoria Francelino AlvesDepartament of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
Marie WallaysLaboratory of Liver Immunology, Hepatology Research Unit, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
Schalk van der MerweLaboratory of Liver Immunology, Hepatology Research Unit, Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium.
Marc FerranteInflammatory Bowel Disease Group, Department of Chronic Diseases and Metabolism, Translational Research in Gastrointestinal Disorders, KU Leuven, Leuven, Belgium.
Tim VanuytselTranslational Research Center for Gastrointestinal Disorders (TARGID), Leuven Intestinal Failure and Transplantation Center (LIFT), University of Leuven, Leuven, Belgium, University Hospitals Leuven, Leuven, Belgium.
John L WallaceDepartment of Physiology and Pharmacology, University of Calgary, Calgary, Canada.
Marcelo N MuscaráDepartament of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
Soraia K P CostaDepartament of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil.
Alexandre Denadai-SouzaLaboratory of Mucosal Biology, Hepatology Research Unit, Department of Chronic Diseases and Metabolism, KU Leuven, Herestraat 49, O&N1, Box 703, 3000, Leuven, Belgium. alexandre.denadai-souza@kuleuven.be.

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 306294/2019-2Conselho Nacional de Desenvolvimento Científico e Tecnológico 312514/2019-0Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 88887.694612/2022-00Fundação de Amparo à Pesquisa do Estado de São Paulo 2016/06146-3Onderzoeksraad, KU Leuven C14/23/135
6 · The paper itself

Abstract

The intestinal epithelial barrier is essential for protection against pathogens and toxins while allowing nutrient and water absorption. Barrier dysfunction is increasingly recognized as a key pathophysiological mechanism in diseases affecting the gastrointestinal (GI) tract and distant organs. Hydrogen sulfide has emerged as an important regulator of intestinal homeostasis. This study investigates the effects of the H₂S-releasing compound 4-hydroxithiobenzamide (TBZ) on epithelial barrier integrity. Although TBZ did not prevent interferon-γ and tumor necrosis factor-α (IFN/TNF)-induced epithelial cell death, it reversed cytokine-induced increases in transepithelial permeability. Notably, TBZ alone increased paracellular permeability but normalized it under inflammatory conditions, indicating a context-dependent effect. H₂S-producing enzymes localized apically in IECs, suggesting subcellular regulation. Transcriptomic analysis identified oxidative phosphorylation as a pathway mediating TBZ’s effects. Functional studies confirmed that TBZ enhances oxidative phosphorylation, while inhibition of complex IV abolished barrier protection. In conclusion, our data indicate that hydrogen sulfide counteracts IFN/TNF-induced epithelial barrier dysfunction through transcriptional and functional enhancement of oxidative phosphorylation.

Indexed as

Hydrogen SulfideInterferon-gammaIntestinal MucosaOxidative PhosphorylationTumor Necrosis Factor-alphaAnimalsCell LineEpithelial CellsHumansIntestinal Barrier FunctionPermeabilityHydrogen SulfideInterferon-gammaTumor Necrosis Factor-alpha

Identifiers

PMID41730958
PMCPMC13031664

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.